1652 Stock Overview
An investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Fusen Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.18 |
| 52 Week High | HK$1.60 |
| 52 Week Low | HK$0.76 |
| Beta | 0.23 |
| 1 Month Change | 34.09% |
| 3 Month Change | -5.60% |
| 1 Year Change | -9.23% |
| 3 Year Change | -65.09% |
| 5 Year Change | -66.38% |
| Change since IPO | -53.54% |
Recent News & Updates
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Recent updates
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20Shareholder Returns
| 1652 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -1.7% | -0.6% | -2.3% |
| 1Y | -9.2% | -7.0% | 0.3% |
Return vs Industry: 1652 underperformed the Hong Kong Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: 1652 underperformed the Hong Kong Market which returned 0.3% over the past year.
Price Volatility
| 1652 volatility | |
|---|---|
| 1652 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.7% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1652's share price has been volatile over the past 3 months.
Volatility Over Time: 1652's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,148 | Dudu Cao | www.fusenyy.com |
Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers cardio cerebrovascular, blood pressure and sugar reduction, tonifying, qi-regulating, anti-anemia, antibacterial and anti-inflammatory, gastrointestinal tract, and expectorant cough category products.
Fusen Pharmaceutical Company Limited Fundamentals Summary
| 1652 fundamental statistics | |
|---|---|
| Market cap | HK$879.77m |
| Earnings (TTM) | -HK$39.15m |
| Revenue (TTM) | HK$610.44m |
1.4x
P/S Ratio-22.3x
P/E RatioIs 1652 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1652 income statement (TTM) | |
|---|---|
| Revenue | CN¥565.61m |
| Cost of Revenue | CN¥266.10m |
| Gross Profit | CN¥299.51m |
| Other Expenses | CN¥335.78m |
| Earnings | -CN¥36.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 52.95% |
| Net Profit Margin | -6.41% |
| Debt/Equity Ratio | 61.7% |
How did 1652 perform over the long term?
See historical performance and comparison